Research statistics

CagriSema research: publications and trials

What has been published on CagriSema: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether CagriSema works or is safe. For what it is and what the studies found, see the CagriSema profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

43

Since 2023

Publications in 2026 so far

24

Through November 15, 2026

Human clinical research

23.8%

10 of 42 classified

Registered clinical trials

10

ClinicalTrials.gov

Randomized controlled trials

8

Publications reporting an RCT in people

Systematic reviews and meta-analyses

12

Preclinical studies

7.1%

2 animal · 0 in vitro · 1 computational

Records that only mention it

17

Not counted above

Status in the library: In clinical trials. Groups: Amylin analogues, GLP-1 receptor agonists. 1 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

CagriSema publications by year and evidence

2023, Human clinical research: 1 of 22023, Other and not yet classified: 1 of 22024, Reviews and meta-analyses: 8 of 82025, Human clinical research: 3 of 92025, Preclinical (animal, in vitro, computational): 2 of 92025, Reviews and meta-analyses: 3 of 92025, Other and not yet classified: 1 of 92026 (to date), Human clinical research: 6 of 242026 (to date), Preclinical (animal, in vitro, computational): 1 of 242026 (to date), Reviews and meta-analyses: 16 of 242026 (to date), Other and not yet classified: 1 of 24Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified01020302023202420252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202310012
202400808
202532319
2026 (to date)6116124

Study types

Review15
Meta-analysis8
Randomized controlled trial8
Systematic review4
Animal study2
Other clinical trial2
Editorial, letter or other2
Computational study1
Not yet classified1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health33
Obesity and weight management33
Endocrinology18
Cardiovascular7
Gastrointestinal2
Musculoskeletal2
Neurological and mental health2

Registered clinical trials

1 of 1 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Recruiting: 3 · Active, not recruiting: 2 · Completed: 2 · Withdrawn: 2 · Not yet recruiting: 1
Phase 1: 2 · Phase 2: 2 · Phase 3: 6

TrialStatusPhaseStartedResults
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNCT07919405 · 1,408 enrolledNot yet recruitingPhase 32026-11—
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251 · 210 enrolledRecruitingPhase 32026-09—
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740WithdrawnPhase 22026-08—
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · 80 enrolledRecruitingPhase 32026-08—
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766WithdrawnPhase 32026-06—
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · 2,500 enrolledRecruitingPhase 32026-05—
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 · 80 enrolledActive, not recruitingPhase 12025-09—
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 · 609 enrolledActive, not recruitingPhase 32025-06—
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · 142 enrolledCompletedPhase 22025-01—
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 · 18 enrolledCompletedPhase 12024-12—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.

    Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times

    PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses

  2. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

    Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses

  3. Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

    Diabetes, metabolic syndrome and obesity : targets and therapy · September 15, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42763732 · DOI 10.2147/dmso.s616418 · Reviews and meta-analyses

  4. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

    BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses

  5. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

    Annals of medicine and surgery (2012) · July 13, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42583410 · DOI 10.1097/ms9.0000000000005353 · Reviews and meta-analyses

  6. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.

    Endocrinology, diabetes & metabolism · July 1, 2026 · Meta-analysis · cited 2 times · open access

    PMID 42207966 · DOI 10.1002/edm2.70248 · Reviews and meta-analyses

  7. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

    Diabetes, obesity & metabolism · March 16, 2026 · Meta-analysis · cited 5 times

    PMID 41834765 · DOI 10.1111/dom.70667 · Reviews and meta-analyses

  8. CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

    The American journal of cardiology · February 26, 2026 · Meta-analysis · cited 1 times

    PMID 41759565 · DOI 10.1016/j.amjcard.2026.02.030 · Reviews and meta-analyses

  9. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

    Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times

    PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses

  10. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

    BMJ (Clinical research ed.) · July 8, 2026 · Systematic review · cited 8 times · open access

    PMID 42419792 · DOI 10.1136/bmj-2026-372161 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

    BMJ (Clinical research ed.) · January 29, 2024 · Systematic review · cited 548 times · open access

    PMID 38286487 · DOI 10.1136/bmj-2023-076410 · Reviews and meta-analyses

  2. What is the pipeline for future medications for obesity?

    International journal of obesity (2005) · February 1, 2024 · Review · cited 331 times · open access

    PMID 38302593 · DOI 10.1038/s41366-024-01473-y · Reviews and meta-analyses

  3. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

    Lancet (London, England) · June 23, 2023 · Randomized controlled trial · cited 330 times · open access

    PMID 37364590 · DOI 10.1016/s0140-6736(23)01163-7 · Human clinical research

  4. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

    The New England journal of medicine · June 22, 2025 · Randomized controlled trial · cited 233 times

    PMID 40544433 · DOI 10.1056/nejmoa2502081 · Human clinical research

  5. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

    The New England journal of medicine · June 22, 2025 · Randomized controlled trial · cited 140 times

    PMID 40544432 · DOI 10.1056/nejmoa2502082 · Human clinical research

Latest publications

  1. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.

    The lancet. Diabetes & endocrinology · November 14, 2026 · Not yet classified · cited 0 times

    PMID 43033821 · DOI 10.1016/s2213-8587(26)00275-5 · Not yet classified

  2. Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.

    Molecular metabolism · October 28, 2026 · Animal study · cited 0 times

    PMID 42951207 · DOI 10.1016/j.molmet.2026.102464 · Animal studies

  3. Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.

    Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times

    PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses

  4. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).

    American heart journal · October 6, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42838477 · DOI 10.1016/j.ahj.2026.107626 · Human clinical research

  5. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

    Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses

  6. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.

    Diabetes therapy : research, treatment and education of diabetes and related disorders · September 28, 2026 · Review · cited 0 times · open access

    PMID 42803913 · DOI 10.1007/s13300-026-01921-0 · Reviews and meta-analyses

  7. Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

    Diabetes, metabolic syndrome and obesity : targets and therapy · September 15, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42763732 · DOI 10.2147/dmso.s616418 · Reviews and meta-analyses

  8. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

    Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times

    PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses

  9. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

    BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses

  10. Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.

    Naunyn-Schmiedeberg's archives of pharmacology · August 17, 2026 · Review · cited 0 times

    PMID 42608559 · DOI 10.1007/s00210-026-05809-5 · Reviews and meta-analyses

Browse all 43 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: CagriSema

((TITLE_ABS:"CagriSema" OR CHEM:"CagriSema")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). CagriSema research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/cagrisema